tetano
Editor, Senior Moderator
CMAJ
. 2020 May 22;cmaj.200642.
doi: 10.1503/cmaj.200642. Online ahead of print.
Efficacy and Safety of Convalescent Plasma for Severe COVID-19 Based on Evidence in Other Severe Respiratory Viral Infections: A Systematic Review and Meta-Analysis
Niveditha Devasenapathy[SUP] 1 [/SUP], Zhikang Ye[SUP] 1 [/SUP], Mark Loeb[SUP] 1 [/SUP], Fang Fang[SUP] 1 [/SUP], Borna Tadayon Najafabadi[SUP] 1 [/SUP], Yingqi Xiao[SUP] 1 [/SUP], Rachel Couban[SUP] 1 [/SUP], Philippe B?gin[SUP] 1 [/SUP], Gordon Guyatt[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) remain uncertain. To support a guideline on COVID-19 management, we conducted a systematic review and meta-analysis of convalescent plasma in COVID-19 and other severe respiratory viral infections.
Methods: In March 2020, we searched international and Chinese biomedical literature databases, clinical trial registries and prepublication sources for randomized controlled trials (RCTs) and nonrandomized studies comparing patients receiving and not receiving convalescent plasma. We included patients with acute coronavirus, influenza and Ebola virus infections. We conducted a meta-analysis using random-effects models and assessed the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
Results: Of 1099 unique records, 6 studies were eligible, and none of these included patients with COVID-19. One nonrandomized study (n = 40) on convalescent plasma in severe acute respiratory syndrome coronavirus (SARS-CoV) provided uninformative results regarding mortality (relative risk [RR] 0.10, 95% confidence interval [CI] CI 0.01 to 1.70). Pooled estimates from 4 RCTs on influenza (n = 572) showed no convincing effects on deaths (4 RCTs, RR 0.94, 95% CI 0.49 to 1.81), complete recovery (2 RCTs, odds ratio 1.04, 95% CI 0.69 to 1.64) or length of stay (3 RCTs, mean difference -1.62, 95% CI -3.82 to 0.58, d). The quality of evidence was very low for all efficacy outcomes. Convalescent plasma caused few or no serious adverse events in influenza RCTs (RR 0.85, 95% CI 0.56 to 1.29, low-quality evidence).
Interpretation: Studies of non- COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events.
. 2020 May 22;cmaj.200642.
doi: 10.1503/cmaj.200642. Online ahead of print.
Efficacy and Safety of Convalescent Plasma for Severe COVID-19 Based on Evidence in Other Severe Respiratory Viral Infections: A Systematic Review and Meta-Analysis
Niveditha Devasenapathy[SUP] 1 [/SUP], Zhikang Ye[SUP] 1 [/SUP], Mark Loeb[SUP] 1 [/SUP], Fang Fang[SUP] 1 [/SUP], Borna Tadayon Najafabadi[SUP] 1 [/SUP], Yingqi Xiao[SUP] 1 [/SUP], Rachel Couban[SUP] 1 [/SUP], Philippe B?gin[SUP] 1 [/SUP], Gordon Guyatt[SUP] 1 [/SUP]
Affiliations
- PMID: 32444482
- DOI: 10.1503/cmaj.200642
Abstract
Background: The safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) remain uncertain. To support a guideline on COVID-19 management, we conducted a systematic review and meta-analysis of convalescent plasma in COVID-19 and other severe respiratory viral infections.
Methods: In March 2020, we searched international and Chinese biomedical literature databases, clinical trial registries and prepublication sources for randomized controlled trials (RCTs) and nonrandomized studies comparing patients receiving and not receiving convalescent plasma. We included patients with acute coronavirus, influenza and Ebola virus infections. We conducted a meta-analysis using random-effects models and assessed the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
Results: Of 1099 unique records, 6 studies were eligible, and none of these included patients with COVID-19. One nonrandomized study (n = 40) on convalescent plasma in severe acute respiratory syndrome coronavirus (SARS-CoV) provided uninformative results regarding mortality (relative risk [RR] 0.10, 95% confidence interval [CI] CI 0.01 to 1.70). Pooled estimates from 4 RCTs on influenza (n = 572) showed no convincing effects on deaths (4 RCTs, RR 0.94, 95% CI 0.49 to 1.81), complete recovery (2 RCTs, odds ratio 1.04, 95% CI 0.69 to 1.64) or length of stay (3 RCTs, mean difference -1.62, 95% CI -3.82 to 0.58, d). The quality of evidence was very low for all efficacy outcomes. Convalescent plasma caused few or no serious adverse events in influenza RCTs (RR 0.85, 95% CI 0.56 to 1.29, low-quality evidence).
Interpretation: Studies of non- COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events.